Bevacizumab has bidirectional regulatory effects on the secretion of basic fibroblast growth factor in glioma cells

Pei, Wei; Zhang, Zhainan; Lin, Miao; Zhou, Bin; Wang, Zhiyong

doi:10.1016/j.cyto.2020.155022

Cited by 8 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In-Cell-Western VEGF expression levels were determined by Incell-western as previously described [9]. Briefly, CRC cells grown in 96-well plates (Jet Bio, Guangzhou) were incubated with 4.5 μM OXA for 6 h. Cancer cells were fixed, permeabilized, blocked, and incubated with rabbit anti-human VEGFA antibody (dilution 1 : 200) and mouse anti-human β-actin antibody (dilution 1 : 400).…”

Section: Ldh Release Assaysmentioning

confidence: 99%

See 1 more Smart Citation

Dichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells

Wang,

Huang

et al. 2024

Dokl Biochem Biophys

Self Cite

View full text Add to dashboard Cite

Although epigallocatechin-3-gallate (EGCG) can potentiate chemotherapeutic drugs at high concentrations, its clinical translation is hampered by exceeding possible concentration thresholds. This study proposes a dichotomous use of low-concentration EGCG in chemotherapy. During the first cycle of combined treatment with oxaliplatin (OXA), low-concentration EGCG antagonized the cytotoxic effect of OXA on colorectal cancer (CRC) cells. However, when OXA was subsequently administered, the sensitivity of CRC cells markedly increased. Although low-concentration EGCG counteracted OXA, it reduced the OXA-induced secretion of vascular endothelial growth factor by tumor cells, thereby contributing to the increase in the sensitivity of tumor cells to the second round of OXA treatment. Therefore, low-concentration EGCG showed potential as a viable adjunct to modulate chemosensitivity in CRC.

show abstract

Section: Ldh Release Assaysmentioning

confidence: 99%

“…ELISA kits were used to verify the VEGF levels in cell culture supernatants in accordance with the instructions provided by the manufacturer and a previous study [9]. Color intensity was assessed using a microplate reader (BioTek Instruments, Epoch) at 450 nm.…”

Section: Elisa Assaysmentioning

confidence: 99%

Dichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells

Wang,

Huang

et al. 2024

Dokl Biochem Biophys

Self Cite

View full text Add to dashboard Cite

show abstract

“…Their receptors (FGFR) are overexpressed and mutated in many types of cancer [106]. High levels of FGF1 and FGF2 o in glioma tissue contribute to angiogenesis, growth, invasion and resistance to treatment of this cancer [106,107]. High levels of FGF1 and FGF2 o in glioma tissue contribute to angiogenesis, growth, invasion and resistance to treatment of this cancer [108,109].…”

Section: Fibroblast Growth Factorsmentioning

confidence: 99%

Molecular Insights into Photodynamic Therapy of Glioma

Aebisher,

Woźnicki,

Bartusik-Aebisher

2024

Preprint

View full text Add to dashboard Cite

Cancers, a large and heterogeneous group of malignancies, are becoming an increasingly important cause of premature mortality worldwide. 2% of these are primary CNS tumors, of which 24% are gliomas. These tumors are diverse, but what they have in common is one of the most unfavorable prognoses among all cancers. A patient's future varies depending on the grade of the diagnosed glioma. To date, however, no standard treatment for grade IV has been established. All glioblastomas eventually undergo progression or recurrence. The current standard of treatment, which includes surgical intervention, radiation therapy and chemotherapy, is therefore far from sufficient. Work is constantly underway to discover a new, effective form of glioma therapy. Photodynamic therapy (PDT) may be one of them. It involves the local or systemic application of a photosensitive compound - a photosensitizer (PS), which accumulates in the affected tissues. Photosensitizer molecules absorb light of the appropriate wavelength, initiating activation processes leading to the formation of reactive oxygen species and selective destruction of inappropriate cells. Currently, this method has been approved for the treatment of several cancers. Research focusing on the effective use of PDT in glioma therapy is already underway, with promising results. In our work, we present molecular insights into PDT of glioma. Based on the available literature, we analyze and systematize the impact of various molecules, proteins, transporters and transmitters on the efficacy of PDT and the effect of PDT on their expression. In addition, we highlight gaps in current knowledge and point out directions for future research that may contribute to the efficacy of PDT glioma.

show abstract

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies

Zhao,

Zeng,

Kang

et al. 2024

Drug Development Research

View full text Add to dashboard Cite

Drug resistance of malignant tumor leads to disease progression be the bottleneck in clinical treatment. Antiangiogenic therapy, which aims to “starve” the tumor by inhibiting angiogenesis, is one of the key strategies in clinical oncology treatments. Recently, dozens of investigational antibody drugs and biosimilars targeting angiogenesis have obtained regulatory approval for the treatment of various malignancies. Moreover, a new generation of bispecific antibodies based on the principle of antiangiogenesis are being advanced for clinical trial to overcome antiangiogenic resistance in tumor treatment or enhance the efficacy of monotherapy. Tumors often develop resistance to antiangiogenesis therapy, presenting as refractory and sometimes even resistant to new therapies, for which there are currently no effective management strategies. Thus, a detailed understanding of the mechanisms mediating resistance to antiangiogenesis antibodies is crucial for improving drug effectiveness and achieving a durable response to antiangiogenic therapy. In this review, we provide a novel perspective on the tumor microenvironment, including antibody structure, tumor stroma, and changes within tumor cells, to analyze the multifactorial reasons underlying resistance to antiangiogenesis antibodies. The review also enumerates biomarkers that indicate resistance and potential strategies for monitoring resistance. Furthermore, based on recent clinical and preclinical studies, we summarize potential strategies and translational clinical trials aimed at overcoming resistance to antiangiogenesis antibodies. This review provides a valuable reference for researchers and clinical practitioners involved in the development of new drugs or therapeutic strategies to overcome antiangiogenesis antibodies resistance.

show abstract

Bevacizumab has bidirectional regulatory effects on the secretion of basic fibroblast growth factor in glioma cells

Cited by 8 publications

References 16 publications

Dichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells

Dichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells

Molecular Insights into Photodynamic Therapy of Glioma

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies

Contact Info

Product

Resources

About